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Abstract
A recent study showed that the Prostate Health Index may avoid unnecessary biopsies in
men with prostate specific antigen 4-10ng/ml and normal digital rectal examination in the
diagnosis of prostate cancer in Hong Kong. This study aimed to conduct an economic evalu-
ation of the impact of adopting this commercially-available test in the Hong Kong public
health service to determine whether further research is justified. A cost-consequence analy-
sis was undertaken comparing the current diagnostic pathway with a proposed diagnostic
pathway using the Prostate Health Index. Data for the model was taken from a prospective
cohort study recruited at a single-institution and micro-costing studies. Using a cut off PHI
score of 35 to avoid biopsy would cost HK$3,000 and save HK$7,988 per patient in biopsy
costs and HK$511 from a reduction in biopsy-related adverse events. The net cost impact of
the change was estimated to be HK$5,500 under base case assumptions. At the base case
sensitivity and specificity for all grades of cancer (61.3% and 77.5% respectively) all grade
cancer could be missed in 4.22% of the population and high grade cancer in 0.53%. The
introduction of the prostate health index into the diagnostic pathway for prostate cancer in
Hong Kong has the potential to reduce biopsies, biopsy costs and biopsy-related adverse
events. Policy makers should consider the clinical and economic impact of this proposal.
Introduction
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide [1].
The incidence of PCa in Chinese men is 10 times lower than the rate in men from Western
Europe but it has increased rapidly in recent years [2,3]. Positive biopsy rates are lower in
Asian men (15–25%) compared with Western European men (30%) and cancer tends to be
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diagnosed later [2,3]. The first steps on the current diagnostic pathway in Hong Kong to evalu-
ate for PCa is a digital rectal examination (DRE) and the prostate specific antigen (PSA) blood
test. In men whose DRE is normal but whose PSA levels are between 4–10 ng/ml the current
diagnostic pathway requires a transrectal ultrasound-guided (TRUS) biopsy. Such biopsies are
invasive and carry considerable risks of post-procedure complications including infection,
fever, acute urinary retention, haematuria and haemospermia. As positive biopsy rates are low,
many biopsies are carried out unnecessarily under the current diagnostic set-up [2].
The Prostate Health Index (PHI) is a commercially available blood test manufactured by
Beckman Coulter Inc. approved by the United States Food and Drug Administration (FDA) in
2012 for use in patients with PSA of 4–10 ng/mL and normal DRE. The test uses a combina-
tion of different forms of PSA (tPSA, fPSA and [–2] proPSA(p2PSA) and has shown improved
ability to predict presence of PCa and clinically significant PCa at biopsy compared to total
PSA [4,5].
Given the improved performance of PHI over total PSA, it has been proposed as a rule-out
test prior to prostate biopsy. The purpose of this study is to provide a preliminary indication of
economic impact were the PHI test to be integrated into the diagnostic pathway prior to pros-
tate biopsy for men in Hong Kong.
Materials and methods
Diagnostic pathway
We mapped the current strategy (biopsy all) and the proposed diagnostic strategy for men
with normal DRE and PSA levels 4–10 ng/ml using information supplied by Hong Kong clini-
cians (JT, PC and CFN). For the proposed strategy, we estimated the costs and consequences
of three different cut-off levels for the test. These pathways were set out as decision trees with a
time horizon covering the diagnostic process up to biopsy (see Fig 1). A Hong Kong public
health service perspective was adopted. Health outcomes differ between the strategies due to
the direct impact of the biopsy and adverse effects following a proportion of biopsies and the
proportion of cancer cases that are missed. Health outcomes relating to the biopsy procedure
itself or complications of the procedure are not considered in this study but they would be pos-
itive under each of the testing strategies as they reduce as the number of biopsies reduces. We
calculate and present the proportion of missed cancers which would likely result from each
testing strategy as well as the costs of the alternative strategies.
Fig 1 shows the current strategy under which all patients undergo TRUS biopsy and the
proposed testing strategy. In the proposed pathway (the lowest branch of the decision tree) all
patients are tested using PHI. Those with a positive result undergo TRUS biopsy. Those with
PHI scores under the threshold (negative result) do not undergo biopsy. In both positive and
negative test result arms there is the possibility of the test result being correct or incorrect
resulting in missed cases of cancer as well as a proportion of unnecessary biopsies.
Data sources
Clinical data to populate the decision trees and costing data for all costs apart from the PHI
test were collected as part of the study reported by Chiu and colleagues [2] (see Table 1 for
inputs to the model). Sensitivity and specificity for three different thresholds of PHI score are
shown in Fig 2. Any accident and emergency attendances and length of hospital stay (where
appropriate) following biopsy were recorded. This resource usage was valued using costs from
the Annual Report for 2016–7 of the Hospital Authority [6]. The PHI test cost was based on
the cost of the test at a Hong Kong clinic to a private user. Costs are not discounted given the
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reported elsewhere (see reference 2) which
provides the context for this economic evaluation.
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short time horizon of the economic evaluation. All data were fully anonymized before access.
The ethics committee waived the requirement for informed consent in this study.
Sensitivity and threshold analysis
One-way sensitivity analysis was undertaken whereby input parameters were varied in turn by
50% of base case value in both directions (whilst all other inputs to the model were held con-
stant) to determine the impact of an over or under-estimation on the base-case results. This
form of sensitivity analysis was undertaken as this allowed decision makers to assess the indi-
vidual impact of each of the input parameters. Where sensitivity analysis showed that the result
was sensitive to an individual parameter threshold analysis was undertaken. This involved
varying the range to determine the highest level at which the cost savings would be reduced to
zero.
Results
Our base-case analysis uses a PHI score of 35 as this was considered the most likely cut-off
level to be acceptable to decision-makers. The introduction of the PHI test at a cut-off of 35
into the diagnostic pathway for men with normal DRE and PSA levels 4–10 ng/ml would save
an estimated HK$5,500 per patient (see Table 2). The majority of the saving results from
approximately 75% of patients avoiding TRUS biopsy as their PHI score was under 35. A fur-
ther cost saving of HK$511 per patient results from a reduction in adverse events following
biopsies. If the cut-off for PHI testing was increased to 55 over 95% of biopsies could be
avoided resulting in an overall cost saving estimated to be in excess of HK$8,000 per patient.
Fig 1. Decision tree illustrating diagnostic strategies for men with suspected prostate cancer, normal digital rectal examination and prostate
specific antigen level 4–10 in Hong Kong. DRE–Digital Rectal Examination, PHI–Prostate Health Index, PSA—Prostate Specific Antigen, TRUS–
Transrectal Ultrasound-guided biopsy. Diamond represents a decision node. Circle represents a probability node.
https://doi.org/10.1371/journal.pone.0215279.g001
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At this cut-off level cost savings are reduced to HK$914. At all cut-off levels the introduction
of PHI results in cost savings although these are greater at higher cut-off levels as more biopsies
are avoided. Testing costs for PHI are included in the analysis at HK$3,000 and it is proposed
to test all patients in this population. Testing costs may reduce under the new testing strategy
as a result of increased volumes. This has not been reflected in the base-case analysis although
test cost is varied in the sensitivity and threshold analyses.
Sensitivity analysis showed that the overall cost saving was sensitive to the cost of biopsy,
the cost of the PHI test and the specificity of the PHI test (see Fig 3). No individual parameter,
when varied within a range 50% above or below the base case would alter the conclusion that
the introduction of the test is likely to be cost saving. Threshold analysis for these parameters
determined values at which the proposed strategy would be cost neutral. These were 24% for
the specificity of the PHI test (base case 77.5%), HK$3,400 for cost of biopsy (base case HK
$10,900) and HK$8,500 for the cost of the test (base case HK$3,000). Table 3 summarises the
base case results, Table 4 the results of sensitivity analysis and Table 5 results of the threshold
analyses. Reducing the sensitivity of the PHI test whilst holding specificity constant results in
more missed cases (all grades of cancer in 7.2% of the population missed at 34% sensitivity,
compared to 4.2% in the base case of 61%) but increases cost savings as more biopsies are
avoided. Lower specificity (with constant sensitivity) results in the same level of missed cases
but savings are reduced as less biopsies are avoided.
Table 1. Inputs to the model and data sources.
Clinical data from Chiu et al study [2]
Cohort size–men recruited between April 2008 and July 2015 with PSA 4-10ng/mL and negative DRE—
undergoing biopsy
569
Prevalence of high-grade cancer in men with PHI score <25 (1/192) 0.5%
Prevalence of any grade cancer in men with PHI score <25 (7/192) 3.6%
Prevalence of high-grade cancer in men with PHI score 25–35 (2/225) 0.9%
Prevalence of any grade cancer in men with PHI score 25–35 (17/225) 7.6%
Prevalence of high-grade cancer in men with PHI score 35–55 (9/131) 6.9%
Prevalence of any grade cancer in men with PHI score 35–55 (30/131) 22.9%
Prevalence of high-grade cancer in men with PHI score >55 (4/21) 19.0%
Prevalence of any grade cancer in men with PHI score >55 (8/21) 38.1%
Prevalence of high-grade cancer in full cohort (16/569) 2.8%
Prevalence of any grade cancer in full cohort (62/569) 10.9%
Clinical data from retrospective analysis of Chiu et al cohort (unpublished)
Proportion of patients attending Accident and Emergency after biopsy (39 patients from 569 undergoing
biopsy)
0.07
Proportion of patients hospitalised after Accident and Emergency attendance (15 patients from 569
undergoing biopsy)
0.38
Mean length of stay in hospital following adverse event after biopsy 4.67
days
Costs HK$
Cost of PHI test to private patient at a Hong Kong clinic (unpublished) 3,000
Cost of Accident and Emergency Department Attendance [6] 1,300
Cost of hospitalisation following biopsy (4.67 days at HK$4,950 per day) [6] 23,116
Cost of TRUS biopsy from hospital finance department analysis (unpublished) 10,900
DRE–Digital Rectal Examination, PHI–Prostate Health Index, TRUS–Transrectal Ultrasound-guided
https://doi.org/10.1371/journal.pone.0215279.t001
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Discussion
Summary of findings
This study found that the adoption of the PHI test for patients with negative DRE and PSA
score 4–10 ng/ml in Hong Kong has the potential to deliver significant cost savings although
there are implications with a proportion of all grade cancers missed. The cost savings arise
because the PHI test stratifies men into those requiring TRUS biopsy and those who can avoid
biopsy and enter the monitoring programme. As biopsy and the adverse events associated with
Fig 2. Test performance of Prostate Health Index at cut-off levels of 25, 35 and 55. Figures in boxes are the cut-off levels for the Prostate Health
Index test from Chiu et al study [2]. Sensitivity/specificity for any grade cancer at different cut-off levels are 88.7%/36.5% at 25, 61.3%/77.5% at 35 and
12.9%/97.4% at 55.
https://doi.org/10.1371/journal.pone.0215279.g002





















100% 10,900 0 698 11,598 - - -
PHI test for all—
cut off 25
66.26% 7,222 3,000 463 10,685 -914 1.23% 0.18%
PHI test for all—
cut off 35
26.71% 2,912 3,000 187 6,098 -5,500 4.22% 0.53%
PHI test for all—
cut off 55
3.69% 402 3,000 26 3,428 -8,170 9.49% 2.11%
PHI–Prostate Health Index, HK$—Hong Kong dollars
https://doi.org/10.1371/journal.pone.0215279.t002
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it are expensive to deal with, a strategy which avoids a relatively small proportion of biopsies
has the potential to deliver savings which exceed the costs of testing all the patients in this pop-
ulation but this must be balanced with the risks of missed cases and the longer term cost and
clinical outcomes. The cost savings are sensitive to the cost of the test and the biopsy as well as
the specificity of the PHI test in this population. This information is useful to decision-makers
as the costs of the biopsy are known, the cost of the test would be known prior to introduction
and cost savings are likely even at relatively low level of specificity (break-even level at 24%
specificity compared to the base case of 78%). This information allows future evidence genera-
tion and decision-making to focus on the consequences of introducing PHI rather than the
costs.
At the base case cut-off of 35, the study data [2] indicated that cancer in 4.2% of the popula-
tion (including 0.53% with high grade cancers) may be missed. However, applying a cut-off of
55 to study data, prostate cancer in 9.5% of the population would have been missed including
Fig 3. Impact of sensitivity analysis. Each parameter plus/minus 50% PHI–Prostate Health Index, A&E–accident and emergency department, HK$—
Hong Kong dollars. Blue reflects the lower bound sensitivity and red the upper bound. Vertical axis crosses at base case savings of HK$5,500.
https://doi.org/10.1371/journal.pone.0215279.g003
Table 3. Base-case results (PHI cut-off 35).
Base case
Cancer cases missed–all grades(high grade) n = 24/569 (3/569) or 4.2% (0.5%)
Cost saving per patient HK$5,500
Made up of:
Additional costs of testing (HK$3,000)
Direct cost savings from biopsies (circa 73% of patients at HK$10,900) HK$7,988
Cost savings from reduction in adverse events HK$511
HK$—Hong Kong Dollars, PHI–Prostate Health Index
https://doi.org/10.1371/journal.pone.0215279.t003
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2.1% with high grade cancer. If the cut-off is reduced to 25 around a third of biopsies could be
avoided with just over 1% of all cancer cases missed including less than 0.2% of high-grade
cancers.
How these results compare to previous studies
The costs results are broadly consistent with three previous economic evaluations of PHI. The
first study by Nichol et al [7] was a budget impact analysis of PHI plus total PSA and percent
free PSA compared to PSA alone. This study evaluated the impact on 1 year total costs of PHI
plus PSA to PSA alone in a screening programme from a US societal perspective in men 50–75
years old. Using thresholds for PHI testing of 2ng/ml and 4ng/ml they estimated cost savings
of $356,647 and $94,219 respectively in a notional insurance company cohort of 100,000 men.
90% of the overall savings came from avoiding unnecessary biopsies. A further study by Nichol
et al [8] extended their previous analysis to a cost-utility analysis with a 25-year time horizon.
This extended analysis found that PHI plus PSA dominated PSA alone strategy for both 2ng/
ml and 4ng/ml thresholds delivering cost savings of $1,199 and $443 respectively together with
utility gains of 0.08 and 0.03. Both Nicholl et al studies used data relevant to the US population
and are not directly applicable to a Chinese population. The final economic evaluation study
identified was Heijnsdijk et al [9] who assessed the cost-effectiveness of using a PHI cut-off of
25 as an add-on to PSA with a cut-off of 3ng/ml in a European screening population aged 50–
75. This study found a reduction in negative biopsies of 23%, a reduction of 17% in costs of
diagnosis and 1% in total cost of prostate cancer.
A recent study [10] extended the Hong Kong cohort from Chui et al [2] with cohorts from
Taiwan, Singapore and Shanghai to make a total of 1,150 men. This later study found higher
Table 4. Sensitivity analysis.
Sensitivity analysis Base case Range (+/- 50%) Results of sensitivity analysis (HK
$)
Lower Upper Lower Upper
Sensitivity of PHI test 61% 31% 100% 5,888 5,011
Specificity of PHI test 78% 39% 100% 1,499 7,824
Prevalence of all grades of cancer 11% 5% 16% 5,748 5,257
Proportion of patients experiencing adverse events 7% 3% 10% 5,242 5,757
Proportion of patients with adverse event requiring hospital 38% 19% 58% 4,831 5,724
Proposed test costs (HK$) 3,000 1,500 4,500 7,000 4,000
Cost of biopsy (HK$) 10,900 5,450 16,350 1,506 9,494
Costs of adverse events without hospitalisation (HK$) 1,300 650 1,950 5,467 5,533
Costs of adverse events with hospitalisation (HK$) 23,116 11,558 34,674 5,277 5,723
HK$—Hong Kong Dollars, PHI–Prostate Health Index
https://doi.org/10.1371/journal.pone.0215279.t004
Table 5. Threshold analysis.
Threshold analysis Base case Value for proposed strategy to be cost neutral
Specificity of PHI test (at 61% sensitivity) 78% 24%
Proposed test costs (HK$) 3,000 8,500
Cost of biopsy (HK$) 10,900 3,400
HK$—Hong Kong Dollars, PHI–Prostate Health Index
https://doi.org/10.1371/journal.pone.0215279.t005
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prevalence of all PCa (13.1% compared to 10.9% in this study) and high grade PCa (5.7% com-
pared to 2.8% in this study). Introduction of a test such as PHI into a population where there
was a higher prevalence would mean that less biopsies could be avoided for the same risk of
false negatives.
Nicholl at al [7] suggests that the negative consequences of missed cases are limited as they
are likely to be found in subsequent screenings [11]. Effectively false negatives represent
delayed rather than missed diagnoses. Moreover, cancers missed tend to have relatively low
Gleason scores and most cancers found 2–4 years after an initial screen are still curable [12–
18]. It is proposed that men below the PHI score of 35 would undergo an annual PSA test until
the age of 78 when mean survival from PCa exceeds life expectancy [19,20]. However, the
extent and grade of false negatives would require further study.
Strengths of this study
This study is a preliminary cost-consequence analysis that indicates that the PHI test is poten-
tially cost-effective in that it is not “dominated” by current practice (i.e. costs more with worse
outcomes) [21]. This represents a necessary but not sufficient condition for cost-effectiveness.
As far as we are aware, it is the first study to examine the potential economic impact of intro-
ducing the PHI test in an Asian population.
The study demonstrates the use of simple economic evaluation in a preliminary assessment
of a diagnostic technology using local data. Another strength of the study is that it was rela-
tively quick and resource light as a result of the simplicity of the model and the availability of
locally relevant data from a previous study. Evidence was taken from a single clinical study [2]
and micro-costings from a single hospital. One-way sensitivity analysis was appropriate as it
allowed decision makers to assess the importance of individual parameters.
Limitations
A significant limitation of this study is that data have been taken from a retrospective analysis
of a cohort taken from a single clinical study [2].
A simplifying assumption was made that all men in the population currently undergo
TRUS biopsy. In a proportion of cases patients and clinicians decide that biopsy is not their
preferred option. In order to change the conclusion of our base case analysis (at a PHI cut-off
of 35) just under 50% of men would need to refuse biopsy. We believe the proportion of men
not undergoing biopsy is substantially lower than this.
Conclusions
The immediate implication of this study for policy-makers is that in the Hong Kong context
PHI is likely to be a cost-saving addition to the diagnostic set-up for prostate cancer in men
with PSA levels of 4-10ng/ml and negative DRE. Although health outcomes have not been
fully quantified, the analysis suggests that, at the proposed cut off of 35, sensitivity could be
retained such that all grade cancer would be missed in 4.2% of the population (and high grade
cancer in 0.53%) whilst a high proportion of biopsies would be avoided. The use of the PHI
test in Hong Kong appears to warrant further investigation, particularly with regard to the
level of missed cases and the longer term health outcomes in these cases. Policy makers in
other jurisdictions may also wish to evaluate the use of Prostate Health Index in the diagnosis
of prostate cancer particularly in Asian populations where the prevalence of prostate cancer is
relatively low [10].
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